Xeomin (incobotulinumtoxinA) / Merz Pharma  >>  Phase 3
Welcome,         Profile    Billing    Logout  

22 Trials

   Remove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xeomin (incobotulinumtoxinA) / Merz Pharma
2021-001634-18: A clinical study to investigate the efficacy and safety of NT 201 in the treatment of lower limb spasticity in children and adolescents with cerebral palsy Badanie kliniczne mające na celu zbadanie skuteczności i bezpieczeństwa stosowania NT 201 w leczeniu spastyczności kończyn dolnych u dzieci i młodzieży z mózgowym porażeniem dziecięcym

Not yet recruiting
3
130
Europe
NT 201, NT 201, Powder for solution for injection, Xeomin
Merz Pharmaceuticals GmbH, Merz Pharmaceuticals GmbH
Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP) Spastyczność kończyn dolnych u dzieci z mózgowym porażeniem dziecięcym., Pediatric lower limb spasticity caused by cerebral palsy. Spastyczność kończyn dolnych u dzieci z mózgowym porażeniem dziecięcym., Diseases [C] - Nervous System Diseases [C10]
 
 
2013-005088-13: Blocs partiels du droit antérieur et du soléaire avec la toxine botulique de type A (Xeomin®) pour l'amélioration de la marche chez l'hémiparétique. Essai randomisé multicentrique contrôlé contre placebo.

Not yet recruiting
3
66
Europe
XEOMIN, Powder for injection, XEOMIN
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
Hémiparésie par accident vasculaire cérébral (AVC) ou traumatise crânien (TC) depuis plus de 6 mois.
 
 
2015-003184-11: Functional effects of botulinum toxin in the hip adductors and subsequent exercise in HSP patients Functionele effecten van botulinetoxine in de heup adductoren en daaropvolgende oefeningen bij HSP patiënten.

Ongoing
3
30
Europe
Solution for injection, Xeomin
Radboud University Medical Centre, Radboud University Medical Centre
Hereditary Spastic Paraplegia Hereditaire Spastische Paraplegie, HSP HSP, Diseases [C] - Nervous System Diseases [C10]
 
 
2017-001216-11: botulinum toxin for the treatment of chronic anal fissure Toxina botulínica para el tratamiento de la fisura anal crónica

Ongoing
3
100
Europe
IncobotulinumtoxinA, IncobotulinumtoxinA, Powder for solution for injection, Xeomin®
Dra. A. Teresa Calderón Duque, NA
Chronic anal fissure Fisura anal crónica, Chronic anal fissure Fisura anal crónica, Not possible to specify
 
 
2016-000740-34: Treatment of continuous tearing with Botulinum Toxin versus the inferior eyelid tightening technique Tratamiento del lagrimeo continuo con Toxina Botulínica frente a la técnica de tensado del párpado inferior

Ongoing
3
24
Europe
IncobotulinumtoxinA, IncobotulinumtoxinA, Powder and solution for solution for injection, Xeomin®
Dr. Borja Maroto Rodríguez, NA
Functional Epifora Epífora funcional, Continuous tearing Lagrimeo continuo, Diseases [C] - Eye Diseases [C11]
 
 

Not yet recruiting
3
150
Europe
Xeomin, Hydrocortancyl, Powder for injection, Suspension for injection, Xeomin, Hydrocortancyl
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), DGOS
Patients suffering from unilateral lateral epicondylitis, persistent for more than 3 months or recurrent and not having responded to at least one reference treatment Patients ayant une épicondylite latérale unilatérale, persistante depuis plus de 3 mois ou récidivante et n'ayant pas répondu à au moins un traitement de référence, NA NA, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2016-003949-28: Efficacy and tolerability of incobotulinumtoxin A in comparison with onabotulinumtoxinA in patients with overactive bladder syndrome. Efficacia e tollerabilit¿ della incobotulinumtoxin A in confronto alla onabotulinumtoxin A nella terapia di pazienti con vescica iperattiva.

Not yet recruiting
3
140
Europe
xeomin, botox, Powder for solution for injection, XEOMIN - 100 UNITA' DL50 POLVERE PER SOLUZIONE INIETTABILE 1 FLACONCINO DI VETRO, BOTOX - 100 UNIT¿ ALLERGAN POLVERE PER SOLUZIONE INIETTABILE 1 FLACONCINO
PROF. ANTONELLA GIANNANTONI - CLINICA UROLOGICA - UNIVERSITà DI PERUGIA, Clinica Urologica ad indirizzo Oncologico
neurogenic overactive bladder Vescica iperattiva neurogena, neurogenic overactive bladder Vescica iperattiva neurogena, Diseases [C] - Symptoms and general pathology [C23]
 
 
2018-002929-36: EFFICACY OF CORTICOIDS VS BOTULINIC TOXIN IN THE TREATMENT OF PLANTAR FASCITIS EFICACIA DE CORTICOIDES VS TOXINA BOTULÍNICA EN EL TRATAMIENTO DE LA FASCITIS PLANTAR

Not yet recruiting
3
70
Europe
IncobotulinumtoxinA, Triamcinolona acetónido, IncobotulinumtoxinA, Triamcinolona acetónido, Powder for solution for injection, Suspension for injection, Xeomin®, TRIGON DEPOT®
Dra. Virginia Raquel Céspedes Nava, NA
Plantar fasciitis Fascitis plantar, Plantar fasciitis Fascitis plantar, Body processes [G] - Physical Phenomena [G01]
 
 
2018-002541-11: Prevention of post-operative Atrial Fibrillation by BOTulinum toxin injections into epicardial fat pads around pulmonary veins in patients undergoing cardiac surgery Prévention de la Fibrillation Atriale postopératoire par l’injection de Toxine BOtulique autour des veines pulmonaires chez les patients ayant une chirurgie cardiaque

Not yet recruiting
3
220
Europe
XEOMIN, Powder for solution for injection, Xeomin® 200 U
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), Ministry of Health
Adult patients with indication for conventional cardiac surgery (CABG, aortic replacement, or ascending aorta surgery) will be eligible Seront éligibles : les patients adultes (>/= 18 ans) avec indication à une chirurgie cardiaque selon les recommandations de la Société Européenne de Cardiologie (ESC) : pontages coronaires, remplacements valvulaires aortiques, remplacements de l’aorte ascendante, Adult patients with indication for conventional cardiac surgery Patients adultes avec indication à une chirurgie cardiaque selon les recommandations de la Société Européenne de Cardiologie, Diseases [C] - Cardiovascular Diseases [C14]
 
 
NCT03758235: Overactive Bladder Syndrome: Incobotulinumtoxin Versus Onabotulinumtoxin

Active, not recruiting
3
140
Europe
IncobotulinumtoxinA 100 UNT Injection [Xeomin], Incobot/A, OnabotulinumtoxinA 100 UNT [Botox], Onabot/A
University Of Perugia
Overactive Bladder Syndrome
09/21
09/21
2022-000842-14: Effectiveness of botulinum toxin A injection in reducing the pain and size of painful scars Efectividad de la inyección de toxina botulínica A para reducir el dolor y tamaño de las cicatrices dolorosas

Not yet recruiting
3
20
Europe
IncobotulinumtoxinA, IncobotulinumtoxinA, Powder for solution for injection, Xeomin®
Dra.Margarita Ramirez&Dra.Ifara Sánchez, NA
painful scars Cicatrices dolorosas, painful scars Cicatrices dolorosas, Not possible to specify
 
 
2019-004113-13: Safety and efficacy study of the simultaneous treatment of upper facial lines (horizontal forehead lines, glabellar frown lines and crows feet) in subjects with moderate to severe upper facial lines.

Not yet recruiting
3
360
Europe
Bocouture, NT 201, Powder for solution for injection, Bocouture (100 Units)
Merz Pharmaceuticals GmbH, Merz Pharmaceutical GmbH
Moderate to severe upper facial lines(horizontal forehead lines, glabellar frown lines, and lateral canthal lines), Moderate to severe upper facial lines(horizontal forehead lines, glabellar frown lines, and crows feed Falten des oberen Gesichtsbereiches(horizontale Stirnfalten, Zornesfalten und Krähenfüße), Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
BOTAF, NCT04075981: Prevention Atrial Fibrillation by BOTulinum Toxin Injections

Recruiting
3
220
Europe
Botulinum Toxin Type A Injection [Xeomin], Xeomin, Drug placebo
Assistance Publique - Hôpitaux de Paris, Merz Pharmaceuticals, Ministry of Health, France
Cardiac Surgery
10/24
09/25
2020-006147-25: Botulinum toxin type A injection in patients with chronic pelvic pain of uterine origin Phase III, single-center, randomized study vs. control group Injection de Toxine botulinique de type A chez des patientes atteintes de douleurs pelviennes chroniques d’origine utérine Étude de phase III, monocentrique, randomisée vs groupe contrôle

Ongoing
3
100
Europe
Toxine botulinique, Powder for solution for injection, XEOMIN 200
Centre de Recherche en Santé de la Femme, Centre de Recherche en Santé de la Femme, Laboratoire MERZ
PATIENTS WITH CHRONIC PELVIC PERINEAL PAIN OF UTERINE ORIGIN WITH VAS>4 PATIENTES PRÉSENTANT DES DOULEURS PELVI-PERINEALES CHRONIQUES D'ORIGINE UTÉRINE AVEC EVA>4, PATIENTS WITH CHRONIC PELVIC PERINEAL PAIN OF UTERINE ORIGIN WITH VAS>4 PATIENTES PRÉSENTANT DES DOULEURS PELVI-PERINEALES CHRONIQUES D'ORIGINE UTÉRINE AVEC EVA>4, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
 
 
NCT05623410: Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines

Active, not recruiting
3
300
RoW
ATGC-110, Clostridium Botulinum Type A, Xeomin®, Incobotulinumtoxin A
ATGC Co., Ltd.
Glabellar Frown Lines
02/23
06/23
2022-004127-40: effectiveness and safety of botulinum toxin type A in doses adapted for patients with severe spasticity efectividad y seguridad de la toxina botulínica tipo A en dosis adaptadas para pacientes con cuadros de espasticidad severa

Not yet recruiting
3
30
Europe
IncobotulinumtoxinA, IncobotulinumtoxinA, Powder for solution for injection, Xeomin
Dra. Nuria Gutierrez Dubón, NA
brain damage oriented spasticity Espasticidad orientada al daño cerebral, spasticity Espasticidad, Not possible to specify
 
 
NCT05980559: Evaluation of BTX Injections in Treatment of Bruxism

Not yet recruiting
3
12
NA
Xeomin
Alexandria University
Bruxism
01/24
04/24
NCT03977493: IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia

Recruiting
3
48
Europe
Xeomin, Placebo - Concentrate
Alain Kaelin, Clinical Trial Unit Ente Ospedaliero Cantonale
Focal Hand Dystonia
12/24
12/24
NCT06205797: To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)

Recruiting
3
312
RoW
HU-045, Xeomin®
Huons Biopharma
Glabellar Lines
11/24
03/25
2021-005496-39: Prospective, randomized, double-blind, placebo controlled, multicenter study assessing the efficacy of intracavernosal Clostridium Botulinum neurotoxin type A (Xeomin®) 100U as add-on therapy to sildenafil 100 mg on demand compared to sildenafil 100 mg on demand for the treatment of erectile dysfunction (ED) not sufficiently responsive to standard therapy with phosphodiesterase type 5 inhibitors Étude multicentrique prospective, randomisée, en double aveugle, contrôlée par placebo, évaluant l'efficacité de la neurotoxine intracaverneuse de Clostridium Botulinum de type A(Xeomin®) 100U en traitement d'appoint au sildénafil 100 mg à la demande par rapport au sildénafil 100 mg à la demande pour le traitement de dysfonction érectile (DE) pas suffisamment sensible au traitement standard avec des inhibiteurs de la phosphodiestérase de type 5

Not yet recruiting
3
226
Europe
XEOMIN, Powder for solution for injection, XEOMIN
Erectile dysfunction Dysfonction érectile, to facilitate long-lasting cavernosal smooth muscle relaxation through an alteration of the balance within the erectile pour faciliter la relaxation durable des muscles lisses caverneux grâce à une altération de l'équilibre au sein du tissu érectile, Diseases [C] - Male diseases of the urinary and reproductive systems [C12]
 
 
NCT05598723: BOTOX® vs. XEOMIN® for Chronic Migraine

Recruiting
3
128
US
IncobotulinumtoxinA (XEOMIN®), Xeomin, OnabotulinumtoxinA (BOTOX®), Botox
Naval Medical Center Camp Lejeune
Chronic Migraine
02/25
08/25
PATTERN, NCT03992404 / 2018-001639-35: Study to Compare the Efficacy and Safety of NT 201 (botulinum Toxin) with Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury

Recruiting
3
600
Europe, Canada, US, RoW
NT 201, IncobotulinumtoxinA, Incobotulinumtoxin A, Xeomin, Botulinum toxin type A (150 kiloDalton), free from complexing proteins, Placebo
Merz Pharmaceuticals GmbH
Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
08/25
04/27

Download Options